AR091006A1 - Formulaciones de testosterona proliposomal - Google Patents
Formulaciones de testosterona proliposomalInfo
- Publication number
- AR091006A1 AR091006A1 ARP130101616A ARP130101616A AR091006A1 AR 091006 A1 AR091006 A1 AR 091006A1 AR P130101616 A ARP130101616 A AR P130101616A AR P130101616 A ARP130101616 A AR P130101616A AR 091006 A1 AR091006 A1 AR 091006A1
- Authority
- AR
- Argentina
- Prior art keywords
- testosterone
- phospholipid
- proliposomal powder
- powder dispersion
- proliposomal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
Abstract
Formulaciones de testosterona donde la testosterona se incorpora en un sistema de fosfolípidos/colesterol para producir una dispersión en polvo proliposomal. Las dispersiones en polvo proliposomales de la presente pueden formularse con excipientes farmacéuticamente aceptables para formar composiciones farmacéuticas. Formas de dosificación oral con recubrimiento entérico como también métodos de tratamiento para la terapia de reemplazo de testosterona. Reivindicación 1: Una dispersión en polvo proliposomal que comprende: (a) testosterona, (b) colesterol, y (c) al menos un fosfolípido, en donde (a) y (b) están presentes en una relación en peso (a):(b) que varía de 1:0,05 a 1:0,30 y (a), (b) y (c) están presentes en una relación en peso (a):((b) + (c)) que varía de 1:1,0 y 1:2,5. Reivindicación 3: Una dispersión en polvo proliposomal conforme con la reivindicación 2 en donde el fosfolípido es distearoil fosfatidilcolina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261644996P | 2012-05-09 | 2012-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR091006A1 true AR091006A1 (es) | 2014-12-30 |
Family
ID=49551459
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130101616A AR091006A1 (es) | 2012-05-09 | 2013-05-09 | Formulaciones de testosterona proliposomal |
Country Status (32)
Country | Link |
---|---|
US (5) | US8957053B2 (es) |
EP (1) | EP2846781B1 (es) |
JP (3) | JP6055088B2 (es) |
KR (1) | KR20150032939A (es) |
CN (2) | CN104780914B (es) |
AP (1) | AP2014008099A0 (es) |
AR (1) | AR091006A1 (es) |
AU (2) | AU2013259509B2 (es) |
BR (1) | BR112014027942A2 (es) |
CA (1) | CA2872779A1 (es) |
CL (1) | CL2014003034A1 (es) |
CO (1) | CO7240373A2 (es) |
CR (1) | CR20140561A (es) |
DO (1) | DOP2015000026A (es) |
EA (2) | EA028809B1 (es) |
EC (1) | ECSP14030572A (es) |
GE (1) | GEP201706754B (es) |
HK (3) | HK1210409A1 (es) |
IL (1) | IL235464B (es) |
IN (1) | IN2014DN10383A (es) |
MA (1) | MA37610B1 (es) |
MX (1) | MX367123B (es) |
MY (1) | MY175305A (es) |
NZ (2) | NZ721900A (es) |
PE (1) | PE20150203A1 (es) |
PH (1) | PH12014502498A1 (es) |
SG (2) | SG11201407349UA (es) |
TN (1) | TN2014000467A1 (es) |
TW (2) | TWI614035B (es) |
UA (1) | UA115058C2 (es) |
WO (1) | WO2013170012A2 (es) |
ZA (2) | ZA201408996B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10213440B2 (en) | 2014-08-20 | 2019-02-26 | Professional Compounding Centers Of America (Pcca) | Oral transmucosal pharmaceutical compositions including testosterone and an aromatase inhibitor |
KR101682821B1 (ko) | 2015-07-21 | 2016-12-06 | 서울대학교산학협력단 | 프로리포솜 제조방법 |
JP6697541B2 (ja) * | 2016-01-07 | 2020-05-20 | ウエスタン ユニバーシティ オブ ヘルス サイエンシーズ | 膀胱癌処置のための処方物 |
WO2017120592A1 (en) * | 2016-01-08 | 2017-07-13 | Western University Of Health Sciences | Proliposomal testosterone undecanoate formulations |
KR102574139B1 (ko) | 2016-07-07 | 2023-09-05 | 삼성전자주식회사 | 무선 충전 모드를 변경하는 장치 및 방법 |
MX2019005185A (es) * | 2016-11-11 | 2019-07-01 | Univ Western Health Sciences | Metodos para tratar las carcinomas uroteliales del tracto superior. |
JP2021503463A (ja) | 2017-11-17 | 2021-02-12 | エボニック オペレーションズ ゲーエムベーハー | コーティングされた硬カプセルを製造する方法 |
US10716774B1 (en) | 2018-01-05 | 2020-07-21 | Yale Pharmaceuticals LLC | Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability |
US20200101085A1 (en) * | 2018-09-28 | 2020-04-02 | Joel Studin | Transpore delivery of drugs and uses thereof |
JP2022533610A (ja) * | 2019-05-15 | 2022-07-25 | エボニック オペレーションズ ゲーエムベーハー | カプセル充填機を用いて、(メタ)アクリレートコポリマー系のコーティングを有する、充填されたハードシェルカプセルを製造する方法 |
CA3137322A1 (en) * | 2019-05-15 | 2020-11-19 | Vinay JAIN | Process for preparing filled hard-shell capsules with cellulose or starch-based coatings with a capsule-filling machine |
EP4009950A4 (en) * | 2019-08-09 | 2023-07-05 | Tesorx Pharma, LLC | PROLIPOSOMAL TESTOSTERONE UNDECANOATE FORMULATIONS |
CN110747271B (zh) * | 2019-12-02 | 2023-07-18 | 延边大学 | 关于pci术后血管损伤-再狭窄程度的标记物 |
JP6945874B2 (ja) * | 2019-12-24 | 2021-10-06 | 一般財団法人バイオダイナミックス研究所 | 経口投与用医薬組成物 |
CN111840240A (zh) * | 2020-05-29 | 2020-10-30 | 仁和堂药业有限公司 | 一种非那雄胺制剂及其应用 |
CN112121003B (zh) * | 2020-09-29 | 2022-02-01 | 江苏集萃新型药物制剂技术研究所有限公司 | 缓释制剂载药材料及其组合物、缓释制剂及其制备方法 |
EP4340838A1 (en) * | 2021-05-19 | 2024-03-27 | Alberto Paz | Orally administered compositions for cancer treatment |
CN114668719B (zh) * | 2022-02-21 | 2023-06-16 | 广东食品药品职业学院 | 双氢睾酮混悬剂与双氢睾酮冻干粉及其制备方法 |
WO2024056062A1 (zh) * | 2022-09-16 | 2024-03-21 | 长春金赛药业有限责任公司 | 一种甾体类激素磷脂组合物及其制备方法 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4744989A (en) | 1984-02-08 | 1988-05-17 | E. R. Squibb & Sons, Inc. | Method of preparing liposomes and products produced thereby |
US5002936A (en) | 1985-04-12 | 1991-03-26 | Seymour Lieberman | Lipophilic complexes of pharmacologically active inorganic mineral acid esters of organic compounds |
US5049388A (en) * | 1986-11-06 | 1991-09-17 | Research Development Foundation | Small particle aerosol liposome and liposome-drug combinations for medical use |
US5338761A (en) | 1988-09-29 | 1994-08-16 | Shiseido Company Ltd. | Emulsified composition |
IE904098A1 (en) | 1989-11-13 | 1991-05-22 | Nova Pharm Corp | Lipospheres for controlled delivery of substances |
US20040175417A1 (en) | 1990-10-19 | 2004-09-09 | Gilead Sciences, Inc. | Amphotericin B liposome preparation |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
JP3017906B2 (ja) | 1993-10-08 | 2000-03-13 | 信越化学工業株式会社 | 腸溶性コーティング剤分散液 |
US6214375B1 (en) | 1996-07-16 | 2001-04-10 | Generex Pharmaceuticals, Inc. | Phospholipid formulations |
US6506783B1 (en) | 1997-05-16 | 2003-01-14 | The Procter & Gamble Company | Cancer treatments and pharmaceutical compositions therefor |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
US6761901B1 (en) * | 2000-05-02 | 2004-07-13 | Enzrel Inc. | Liposome drug delivery |
US6858596B2 (en) * | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
WO2002051426A2 (en) | 2000-12-22 | 2002-07-04 | A Glenn Braswell | COMPOSITIONS AND METHODS FOR TREATING SEXUAL DYSFUNCTIONS, IMPROVING SEXUAL ACTIVITY AND INCREASING TESTOSTERONE LEVELS, AND IMPROVING MUSCLE STRENGTH AND MASS |
US6534080B2 (en) | 2001-02-12 | 2003-03-18 | Super Gen, Inc. | Method for administering camptothecins via injection of pharmaceutical composition comprising coated particles of a camptothecin |
US6759058B1 (en) * | 2001-04-25 | 2004-07-06 | Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences | Enteric-coated proliposomal formulations for poorly water soluble drugs |
US8658202B2 (en) * | 2001-04-25 | 2014-02-25 | Western University Of Health Sciences | Coated drug delivery formulations |
US20040115226A1 (en) | 2002-12-12 | 2004-06-17 | Wenji Li | Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same |
JO2505B1 (en) * | 2003-03-14 | 2009-10-05 | باير شيرنغ فارما اكتنجيسيلشافت | Pharmacy methods and formulations for obtaining acceptable serum testosterone levels |
EP1624857A2 (de) | 2003-05-12 | 2006-02-15 | Novosom AG | Injizierbare depots aus liposomalen aggregaten zur wirkstoffverabreichung |
ATE509618T1 (de) | 2003-11-05 | 2011-06-15 | Elan Pharma Int Ltd | Nanoteilchenförmige zusammensetzungen mit einem peptid als oberflächenstabilisator |
US20060051406A1 (en) | 2004-07-23 | 2006-03-09 | Manjeet Parmar | Formulation of insoluble small molecule therapeutics in lipid-based carriers |
WO2006062506A1 (en) * | 2004-12-03 | 2006-06-15 | Enzrel, Inc. | Chitosan-coated liposome drug delivery of antioxidant or anti-inflammatory compounds |
CA2631875A1 (en) | 2005-12-06 | 2007-10-04 | Rigel Pharmaceuticals, Inc. | Formulation of insoluble small molecule therapeutics in lipid-based carriers |
US20070154403A1 (en) | 2006-01-05 | 2007-07-05 | Thomas Skold | Oral, Pulmonary and Transmucosal Delivery Composition |
CA2660310C (en) | 2006-03-30 | 2015-04-21 | The Research Foundation Of State University Of New York | Compositions of less immunogenic and long-circulating protein-lipid complexes |
WO2008114274A1 (en) * | 2007-03-19 | 2008-09-25 | Fresenius Kabi Onclology Ltd. | Proliposomal and liposomal compositions |
US11304960B2 (en) * | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
US9492387B2 (en) * | 2010-10-29 | 2016-11-15 | Western University Of Health Sciences | Ternary mixture formulations |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
CA2845118A1 (en) | 2011-08-18 | 2013-02-21 | Monosol Rx, Llc | Steroid hormone delivery systems and methods of preparing the same |
-
2013
- 2013-05-09 AU AU2013259509A patent/AU2013259509B2/en not_active Ceased
- 2013-05-09 JP JP2015511696A patent/JP6055088B2/ja not_active Expired - Fee Related
- 2013-05-09 AR ARP130101616A patent/AR091006A1/es unknown
- 2013-05-09 CN CN201380032890.8A patent/CN104780914B/zh not_active Expired - Fee Related
- 2013-05-09 CA CA2872779A patent/CA2872779A1/en not_active Abandoned
- 2013-05-09 WO PCT/US2013/040325 patent/WO2013170012A2/en active Application Filing
- 2013-05-09 GE GEAP201313659A patent/GEP201706754B/en unknown
- 2013-05-09 MY MYPI2014703308A patent/MY175305A/en unknown
- 2013-05-09 BR BR112014027942A patent/BR112014027942A2/pt active Search and Examination
- 2013-05-09 EA EA201492047A patent/EA028809B1/ru not_active IP Right Cessation
- 2013-05-09 IN IN10383DEN2014 patent/IN2014DN10383A/en unknown
- 2013-05-09 CN CN201810024730.3A patent/CN108096192A/zh active Pending
- 2013-05-09 SG SG11201407349UA patent/SG11201407349UA/en unknown
- 2013-05-09 EP EP13787438.4A patent/EP2846781B1/en active Active
- 2013-05-09 MA MA37610A patent/MA37610B1/fr unknown
- 2013-05-09 PE PE2014002002A patent/PE20150203A1/es active IP Right Grant
- 2013-05-09 TW TW102116691A patent/TWI614035B/zh not_active IP Right Cessation
- 2013-05-09 SG SG10201702240TA patent/SG10201702240TA/en unknown
- 2013-05-09 AP AP2014008099A patent/AP2014008099A0/xx unknown
- 2013-05-09 TW TW106138648A patent/TWI664982B/zh not_active IP Right Cessation
- 2013-05-09 MX MX2014013450A patent/MX367123B/es active IP Right Grant
- 2013-05-09 NZ NZ721900A patent/NZ721900A/en not_active IP Right Cessation
- 2013-05-09 NZ NZ702634A patent/NZ702634A/en not_active IP Right Cessation
- 2013-05-09 KR KR1020147034548A patent/KR20150032939A/ko not_active Application Discontinuation
- 2013-05-09 EA EA201791738A patent/EA201791738A1/ru unknown
- 2013-09-05 UA UAA201413186A patent/UA115058C2/uk unknown
-
2014
- 2014-01-07 US US14/149,227 patent/US8957053B2/en not_active Expired - Fee Related
- 2014-11-02 IL IL235464A patent/IL235464B/en active IP Right Grant
- 2014-11-04 TN TN2014000467A patent/TN2014000467A1/fr unknown
- 2014-11-07 CL CL2014003034A patent/CL2014003034A1/es unknown
- 2014-11-07 PH PH12014502498A patent/PH12014502498A1/en unknown
- 2014-12-04 CR CR20140561A patent/CR20140561A/es unknown
- 2014-12-08 ZA ZA2014/08996A patent/ZA201408996B/en unknown
- 2014-12-09 EC ECIEPI201430572A patent/ECSP14030572A/es unknown
- 2014-12-09 CO CO14270756A patent/CO7240373A2/es unknown
-
2015
- 2015-01-26 US US14/604,985 patent/US9445995B2/en active Active
- 2015-02-12 DO DO2015000026A patent/DOP2015000026A/es unknown
- 2015-09-17 HK HK15109133.2A patent/HK1210409A1/xx unknown
- 2015-12-21 HK HK15112557.3A patent/HK1211499A1/xx not_active IP Right Cessation
- 2015-12-22 ZA ZA2015/09340A patent/ZA201509340B/en unknown
-
2016
- 2016-08-29 US US15/250,169 patent/US9623033B2/en not_active Expired - Fee Related
- 2016-09-19 US US15/268,917 patent/US9844557B2/en not_active Expired - Fee Related
- 2016-12-01 JP JP2016234097A patent/JP6208842B2/ja not_active Expired - Fee Related
-
2017
- 2017-09-07 JP JP2017172142A patent/JP6368020B2/ja not_active Expired - Fee Related
- 2017-11-29 US US15/825,530 patent/US20180303850A1/en not_active Abandoned
- 2017-12-07 AU AU2017272249A patent/AU2017272249B2/en not_active Ceased
-
2018
- 2018-11-23 HK HK18114995.6A patent/HK1255929A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR091006A1 (es) | Formulaciones de testosterona proliposomal | |
ECSP14013217A (es) | 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk. | |
MX2013011655A (es) | Forma de dosis unitaria para administracion oral. | |
EA201690102A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
DOP2013000252A (es) | FORMULACION PARA ANTICUERPO ANTI-a4ß7 | |
EA201491479A1 (ru) | Производные лупановых тритерпеноидов и их фармацевтическое применение | |
BR112012016853A2 (pt) | "composições farmacêuticas para administração oral de peptídeos de insulina". | |
MY165888A (en) | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation | |
CU20140037A7 (es) | Derivados de estra- 1,3,5(10), 16- tetraen- 3- carboximida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
MX367926B (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
CO7101244A2 (es) | Fenilimidazopirazoles sustituidos y su uso | |
MX2016009217A (es) | Inmunoterapia basada en liposomas. | |
BR112014024033A8 (pt) | Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes | |
BR112015010651A2 (pt) | composição antiparasitária de amplo espectro de nitazoxanida, probióticos e prebióticos | |
MX2016005900A (es) | Profarmaco mutuo que comprende acidos grasos de cadena corta y zebularina o 1'-ciano-citarabina para tratamiento del cancer. | |
MX362905B (es) | Tratamiento de combinacion. | |
MX2015010594A (es) | Esteres de testosterona de cadena larga lipobalanceados para suministro oral. | |
BR112013025610A2 (pt) | uso de um metapneumovírus aviário vivo, e, composição farmacêutica | |
CO6602160A2 (es) | Terapia de b12 oral | |
EA201592261A1 (ru) | Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой | |
MX365096B (es) | Uso de paricalcitol en el tratamiento de la anemia inflamatoria. | |
BR112014015193A2 (pt) | composição enriquecida com glicoproteína como um aditivo para alimento e/ou ração e/ou como um agente terapêutico | |
IN2013MU01330A (es) | ||
TN2013000213A1 (en) | Solid dosage forms of oleyl phosphocholine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |